Zhongshan Golden Bridge Biotechnology

Zhongshan Golden Bridge Biotechnology (ZSGB-BIO) is a prominent Chinese biotechnology company specializing in the development and manufacture of reagents for clinical pathology and cancer diagnostics. Founded in the early 1990s, the company is a market leader in China for immunohistochemistry (IHC) products, providing high-sensitivity detection kits, primary antibodies, and molecular diagnostic tools such as FISH probes. Its proprietary Elivision and Supervision detection systems are widely adopted in hospitals and laboratories for precise tissue-based diagnosis. In 2013, the company was acquired by OriGene Technologies, which integrated ZSGB-BIO's manufacturing and distribution capabilities into its global life sciences portfolio. ZSGB-BIO continues to play a critical role in the standardization of diagnostic pathology across the Chinese healthcare system.